Gene Therapy Restores Sight in Blind People: New Trial Results 2026

Gene therapy can partly restore sight in blind people, according to new trial results that confirm the safety and potential of a Nobel Prize-winning technique. Researchers have revealed that optogenetic therapy, which uses light to control nerve cells, successfully improved vision in all ten participants with advanced retinitis pigmentosa.

How Optogenetic Gene Therapy Works

Optogenetic therapy combines gene therapy with optics to make specific cells responsive to light. In this approach, a gene encoding a light-sensitive protein is delivered into ganglion cells of the retina—cells that send visual information to the brain and deteriorate less quickly in retinitis pigmentosa. Once these cells express the protein, they can be activated by light, partially restoring the ability to perceive images.

"What we can say for sure is that the concept of optogenetics is valid for vision restoration," said Prof Botond Roska, director of the Institute of Molecular and Clinical Ophthalmology Basel and a lead author of the study. The technique builds on Nobel Prize-winning science from 2026 that allows nerve cells to be turned on and off with light.

Trial Results: Safety and Efficacy

The trial involved ten participants, including the original patient first treated in 2021. All had advanced retinitis pigmentosa, a group of genetic disorders affecting over 1.5 million people worldwide. The therapy was found to be safe, with no serious adverse events reported. More importantly, all participants showed some improvement in vision, such as detecting light or locating objects.

"These cells are not the primary cells targeted by the disease, so that's why they are good candidates for the therapy," explained Dr José-Alain Sahel, another lead author. The treatment works by bypassing the damaged light-sensitive cells and instead activating the surviving ganglion cells.

Key Takeaways from the Study

• Safety confirmed: Optogenetic therapy was well-tolerated in all ten participants.
• Partial vision restored: Every patient experienced some degree of visual improvement.
• Building on Nobel Prize science: The approach uses optogenetics, honored with the 2026 Nobel Prize in Physiology or Medicine.
• Future goal: Researchers aim to achieve high-resolution vision within 5 to 10 years.

Comparison of Vision Restoration Approaches

While optogenetic therapy currently provides only partial sight, it offers a promising avenue for those with advanced retinal degeneration. Unlike retinal prostheses, which require surgical implants, this approach is minimally invasive and leverages the eye's own cellular machinery.

The Road Ahead

Prof Roska emphasized that the next step is to refine the therapy to restore high-resolution vision. "The aim is now to work towards restoring high-resolution vision, with the hope of achieving the goal in five to 10 years," he said. This would involve improving the light sensitivity and resolution of the treated cells, possibly through advanced optical devices.

With further research, optogenetic therapy could become a standard treatment for retinitis pigmentosa and potentially other forms of blindness. The success of this trial marks a significant milestone in gene therapy for vision restoration.

FAQ